[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,613,080
  • Shares Outstanding, K 171,236
  • Annual Sales, $ 1,072 M
  • Annual Income, $ 391,000 K
  • EBIT $ 81 M
  • EBITDA $ 87 M
  • 60-Month Beta 0.86
  • Price/Sales 3.41
  • Price/Cash Flow 24.03
  • Price/Book 2.93

Options Overview Details

View History
  • Implied Volatility 37.79% (+1.76%)
  • Historical Volatility 34.46%
  • IV Percentile 5%
  • IV Rank 5.41%
  • IV High 98.54% on 01/09/26
  • IV Low 34.32% on 12/30/25
  • Expected Move (DTE 24) 1.99 (9.43%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 53
  • Volume Avg (30-Day) 321
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 14,418
  • Open Int (30-Day) 13,240
  • Expected Range 19.11 to 23.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.07
  • Number of Estimates 9
  • High Estimate $0.14
  • Low Estimate $-0.01
  • Prior Year $0.16
  • Growth Rate Est. (year over year) -56.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.30 +3.94%
on 05/19/26
23.07 -8.54%
on 05/06/26
-1.14 (-5.13%)
since 04/22/26
3-Month
19.89 +6.08%
on 03/19/26
25.36 -16.80%
on 02/27/26
-2.89 (-12.05%)
since 02/20/26
52-Week
19.69 +7.16%
on 10/13/25
28.35 -25.57%
on 12/23/25
-0.45 (-2.09%)
since 05/22/25

Most Recent Stories

More News
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide...

ACAD : 21.10 (-1.03%)
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms

ACADIA Pharmaceuticals (NASDAQ:ACAD) executives said the company is focused on expanding its two commercial brands while preparing for several clinical data readouts in neuropsychiatric disorders, according...

ACAD : 21.10 (-1.03%)
Acadia: Q1 Earnings Snapshot

Acadia: Q1 Earnings Snapshot

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

- First quarter DAYBUE ® GAAP net sales of $101 million, up 20% year-over-year; successful launch of DAYBUE STIX underway - First quarter...

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals Reports Tuesday With Rett Syndrome Revenue Still Under the Microscope

Barchart Research What to Expect from ACAD Earnings ACAD Generated May 5, 2026 Current Price $22.35 EPS Estimate $$0.04 Consensus Rating Moderate Buy Average Move 7.83% Acadia Pharmaceuticals Reports Tuesday...

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has decided to retire for personal reasons...

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference ...

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of Neurology (AAN) Annual Meeting,...

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026

Company to host conference call and webcast on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Time

ACAD : 21.10 (-1.03%)
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome

-- DAYBUE STIX is a new powder formulation of trofinetide -- Recently published expert consensus recognizes trofinetide as part of the standard of care for Rett syndrome...

ACAD : 21.10 (-1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative medicines to address the unmet medical needs in central nervous system (CNS) disorders. The company's sole marketed drug Nuplazid (pimavanserin) is the first and the only FDA-approved treatment for hallucinations...

See More

Key Turning Points

3rd Resistance Point 21.97
2nd Resistance Point 21.79
1st Resistance Point 21.44
Last Price 21.10
1st Support Level 20.91
2nd Support Level 20.73
3rd Support Level 20.38

See More

52-Week High 28.35
Fibonacci 61.8% 25.04
Fibonacci 50% 24.02
Fibonacci 38.2% 23.00
Last Price 21.10
52-Week Low 19.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.